To evaluate the incidence and management of cutaneous immune-related adverse events (d-irAEs) in melanoma patients treated with immune checkpoint inhibitors (ICIs), highlighting their impact on patient management.
Key Findings:
d-irAEs range from mild to life-threatening and can occur at any stage of treatment.
Dermatologic adverse events are the most common irAEs, affecting 30-40% of patients on anti-PD-1 therapy, with specific data points.
Real-world reporting of mild-to-moderate d-irAEs is significantly underreported, impacting patient management.
Interpretation:
Continuous dermatological surveillance and a multidisciplinary approach are essential for early detection and management of d-irAEs in melanoma patients receiving ICIs, with implications for clinical practice.
Limitations:
Underreporting of mild-to-moderate d-irAEs in clinical practice, which may skew understanding of their true incidence.
Variability in the incidence and severity of skin toxicities, affecting treatment strategies.
Conclusion:
A systematic approach to reporting d-irAEs is crucial for personalized patient management and improving outcomes in melanoma treatment, emphasizing the importance of addressing these events.
Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread
